

# Comparative Pancreas Induction Study

<b>Submission date</b> 27/01/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 27/01/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 26/08/2009	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr J.W. Fijter, de

**Contact details**  
Leiden University Medical Center  
Department of Nephrology  
C3-P22  
P.O. Box 9600  
Leiden  
Netherlands  
2300 RC  
+31 (0)71 5262169  
jwdefijter@lumc.nl

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

# Study information

## Scientific Title

Added 26/08/09: An open label, randomised, study to assess the efficacy and safety of Zenapax® (daclizumab) or a single high dose of Anti-Thymocyte Globulin (ATG-Fresenius®) for the prevention of acute rejection in patients receiving de novo simultaneous pancreas kidney transplantation treated with CellCept®, Neoral® and corticosteroids.

## Acronym

COMPAS

## Study objectives

Equal in efficacy to prevent (biopsy-confirmed) early graft rejection and steroid-resistant rejection episodes in the first 6 months after a first simultaneous pancreas kidney transplantation.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Received from local medical ethics committee

## Study design

Multicentre randomised open label active controlled parallel group trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Renal transplant, Pancreas transplantation

## Interventions

Randomisation for the type of induction therapy:

1. Zenapax® (5 gifts of 1 mg/kg, with a maximum of 100 mg per dose, diluted in 50 ml of sterile 0.9% sodium chloride solution). The first dose will be administered intravenously before reperfusion of the first allograft. Subsequent doses of Zenapax® will be given 2, 4, 6, and 8 weeks after transplantation.
2. ATG-Fresenius® (single high dose of 9 mg/kg, diluted in 500 ml of sterile 0.9% sodium chloride solution). The iv infusion starts immediately after the central line is in place and the dose will be

administered before reperfusion of the first allograft.

All patients will be given 500 mg Solu-Medrol as an iv infusion thirty minutes before operation. All patients will receive mycophenolate mofetil (2 g/day), cyclosporin A (CsA) and prednisone. Dosing of CsA (target trough levels) and prednisone will be according to current hospital practice, aiming at cyclosporine trough levels of 200-300 ng/ml in the first three months, and 100-200 ng/ml thereafter.

## **Intervention Type**

Drug

## **Phase**

Not Specified

## **Drug/device/biological/vaccine name(s)**

Anti-Thymocyte Globulin (ATG-Fresenius®), daclizumab (Zenapax®), mycophenolate mofetil (MMF) (CellCept®), cyclosporin (Neoral®), prednisone

## **Primary outcome measure**

The prevention of biopsy proven early graft rejection and steroid-resistant rejection episodes in the first 6 months after simultaneous pancreas kidney transplantation.

## **Secondary outcome measures**

1. Recurrence of autoimmune disease parameters
2. Time to first rejection, time after last prophylactic dose and number of steroid-resistant rejection episodes at 3 and 6 months after transplantation
3. Graft and patient survival
4. Immunophenotyping peripheral blood lymphocytes (CD3, CD4, CD8 and CD25 respectively)
5. Adverse events and opportunistic infections
6. After the first year, patient and graft survival and the occurrence of graft dysfunction will be monitored and documented according to local practice

## **Overall study start date**

01/10/1999

## **Completion date**

01/06/2005

# **Eligibility**

## **Key inclusion criteria**

1. Type 1 diabetics (C-peptide negative) with (pre)terminal or end-stage renal failure scheduled to receive a simultaneous pancreas kidney cadaveric transplantation, with either bladder or enteric drainage
2. Patients scheduled to receive mycophenolate mofetil (CellCept®), cyclosporin (Neoral®) and corticosteroids as basis immunosuppression
3. Male and female patients >18 years old
4. Patients capable of understanding the purpose and risks of the study and from whom informed consent has been obtained

## **Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

40

**Key exclusion criteria**

1. Pancreas after kidney transplant (PAK), pancreas transplant alone (PTA), segmental pancreatic transplant
2. Duct occlusion technique
3. Induction therapy with OKT3 planned
4. Pregnant or nursing women and women unwilling to use adequate contraception during, and three months following the conclusion of treatment with MMF
5. Patients scheduled to receive FK 506 (tacrolimus) or Azathioprine as basis immunosuppression
6. Patients with severe gastrointestinal disorders, that interfere with their ability to receive or absorb oral medication and patients with severe diarrhea
7. Patients with active peptic ulcer disease
8. Patients or their donors with serologic evidence of HIV, Hepatitis C Virus (HCV) or Hepatitis B Surface Antigen (HBsAg) in the past
9. Patients with malignancies (current or history within last 5 years) except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully
10. Patients with systemic infection requiring therapy at the time of entry to the study
11. Patients being treated with unlicensed, investigational drugs or other prohibited medication
12. Patients with any form of substance abuse or psychiatric disorder which in the opinion of the investigator might invalidate patients communication with the clinician
13. Patients with known hypersensitivity to daclizumab or to any of the components of this product

**Date of first enrolment**

01/10/1999

**Date of final enrolment**

01/06/2005

**Locations**

**Countries of recruitment**

Netherlands

**Study participating centre**

**Leiden University Medical Center**

Leiden  
Netherlands  
2300 RC

## Sponsor information

**Organisation**

Leiden University Medical Centre (LUMC) (Netherlands)

**Sponsor details**

Albinusdreef 2  
P.O. Box 9600  
Leiden  
Netherlands  
2300 RC

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/027bh9e22>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Roche Nederland BV (Netherlands)

**Funder Name**

Fresenius Medical Care (Germany)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/07/2007		Yes	No